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Transplant candidates are permitted to register on
multiple waiting lists. We examined multiple-listing
practices and outcomes, using data on 81 481 kid-
ney and 26 260 liver candidates registered between
7/1/95 and 6/30/00. Regression models identified
factors associated with multiple-listing and its ef-
fect on relative rates of transplantation, waiting list
mortality, kidney graft failure, and liver transplant
mortality. Overall, 5.8% (kidney) and 3.3% (liver) of
candidates multiple-listed. Non-white race, older age,
non-private insurance, and lower educational level
were associated with significantly lower odds of
multiple-listing. While multiple-listed, transplantation
rates were significantly higher for nearly all kidney and
liver candidate subgroups (relative rate [RR] = 1.42–
2.29 and 1.82–7.41, respectively). Waiting list mortal-
ity rates were significantly lower while multiple-listed
for 11 kidney subgroups (RR = 0.22–0.72) but signifi-
cantly higher for 7 liver subgroups (RR = 1.44–5.93),
suggesting multiple-listing by healthier kidney can-
didates and sicker liver candidates. Graft failure was
10% less likely among multiple-listed kidney recipi-
ents. Multiple- and single-listed liver recipients had
similar post-transplant mortality rates. Although spe-
cific factors characterize those transplant candidates
likely to multiple-list, transplant access is significantly
enhanced for almost all multiple-listed kidney and liver
candidates.
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Introduction
The gap between the number of transplantable organs
from deceased donors and the number of patients await-
ing transplantation continues to increase each year (1).
The complex debate over the merits, ethics, propriety, and
even legality of patients placing their names on more than
one waiting list for transplantation, a practice known as
multiple-listing, persists amid the growing imbalance be-
tween supply and demand. After the Organ Procurement
and Transplantation Network (OPTN) was formed by the
National Organ Transplant Act of 1984 (2), policies designed
to promote fair and equitable organ allocation were devel-
oped and adopted in 1987 by the Board of Directors of the
United Network for Organ Sharing, the organization acting
as the OPTN contractor. Multiple-listing was explicitly per-
mitted. In early 1988, equity concerns led to a recommen-
dation to rescind the option of multiple-listing. However,
based on public comments received later that year, the pol-
icy remained. Proposed bans on multiple-listing were heat-
edly discussed again in the 1990s, but no further policy ac-
tions were taken or implemented. During the past 2 years,
the OPTN has again begun to debate the issue. Aside from
kidney transplant candidates in the state of New York (3),
patients anywhere in the United States are permitted to
multiple-list.
Opponents maintain that the opportunity to multiple-list
is not available to (or even known by) all transplant can-
didates and is utilized by only a small proportion of
them. Multiple-listed candidates, it is argued, have an
unfair advantage in terms of access to organs. Further,
the characteristics of those who multiple-list differ sig-
nificantly from those who do not, which appears to ex-
acerbate existing demographically defined inequalities in
transplant access (4). Advocates of multiple-listing assert
that patient choice is an important element of US med-
ical practice and that those who have interest and the
means to multiple-list should be free to do so. Further-
more, regional differences in access to transplant organs,
which are of striking magnitude (5,6), may be ameliorated
through the practice of multiple-listing by increasing ef-
fective organ distribution areas. This effect is of very lim-
ited impact, however, as it occurs on a patient-by-patient
basis.
Few systematic studies of the practice and outcomes
of multiple-listing for kidney transplantation have been
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published (3,4,7–9), and none have been published relat-
ing to liver transplantation. We report here the results of
analyses concerning the relationship of multiple-listing to
access to transplantation and outcomes for patients with
end-stage renal and liver disease.
Materials and Methods
Data sources
The study used the data system of the Scientific Registry of Transplant
Recipients (SRTR) regarding access to transplantation, waiting list mortality,
and post-transplantation graft and patient survival. The SRTR data system
includes data on all wait-listed candidates and transplant recipients in the US
submitted by the members of the OPTN, and is supplemented by mortality
information from the Social Security Death Master File (10).
All candidates added to the kidney transplant waiting list between July 1,
1995 and June 30, 2000 were eligible for inclusion in the access to kidney
transplantation and kidney waiting list mortality analyses, and all recipients
of cadaveric kidney transplants between July 1, 1995 and June 30, 2000
were eligible for inclusion in the kidney graft survival analysis. All candi-
dates added to the liver waiting list between July 1, 1997 and June 30,
2000 were eligible for inclusion in the access to liver transplantation and
waiting list mortality analyses, and all recipients of cadaveric liver trans-
plants between July 1, 1997 and June 30, 2000 were eligible for inclusion
in the liver graft survival analysis. Kidney candidates or recipients who were
also registered for a simultaneous kidney-pancreas transplant while waiting
for a kidney-only transplant or at kidney transplantation were not included
in any analyses. The study samples numbered 81 481 kidney candidates,
38 505 kidney recipients, 26 260 liver candidates, and 12 396 liver
recipients.
Analytical methods
All statistical analyses were performed using SAS 8.0 (11). Multiple-listing
was defined as concurrent listings with two or more transplant centers not
associated with the same organ procurement organization (OPO). A logistic
regression model was developed to evaluate candidate and OPO character-
istics associated with whether or not a candidate was ever multiple-listed,
defined as any duration of multiple-listing.
We explored OPO waiting time and distance between listing transplant
centers to ascertain whether these factors influenced patients’ choices of
transplant center for second listing. We used the following rules for select-
ing the OPO of first listing and the OPO of second listing. Most patients with
multiple-listings were only on waiting lists concurrently at two centers in
different OPOs, and added the second listing after the first listing date. For
patients who initially listed at centers in more than one OPO on the same
day, we randomly selected one OPO as the first listing OPO, and another
(usually the remaining) OPO as the second listing OPO. For patients who
were initially listed in the service area of one OPO and then simultaneously
added listings at two or more OPO service areas on a subsequent date, we
randomly chose one of the subsequent OPOs as the second listing OPO.
The application of these rules was only required for 2.4% of kidney cases
and 1.0% of liver cases.
After identifying the OPO associated with the first listing and subsequent
listings, we calculated the geographic distance between the listing trans-
plant centers in the two OPOs. We also examined the time until 25% of
all patients who entered the waiting list were transplanted in each OPO by
year to determine if multiple-listed patients chose a second listing center
in an OPO with a shorter waiting time. Waiting time until transplant was
calculated as the time (in days) after placement on the waiting list, by which
25% of all patients initially placed on the waiting list during that year had
been removed from the waiting list for receiving a transplant (cadaveric or
living). The 25th percentile was chosen because median time to transplant
for listings during the study period had not been reached for some OPOs
by the study end date. A Kaplan-Meier analysis was used to determine the
25th percentile of time until transplant, with patient waiting time censored
on (a) May 1, 2002 for those candidates still waiting on that date; or (b) the
date of removal from the waiting list for recovery. The 25th percentile of
transplant was calculated by OPO and year of listing for all patients in the
OPO. It was then matched to each multiple-listed patient by first or second
OPO and year listed at that OPO.
For recipients who were multiple-listed at the time of transplantation, we
determined whether the transplant took place at the center in the origi-
nal listing OPO or a subsequent center in another OPO. The proportion of
multiple-listed recipients who transferred their active waiting time to the
second listing center’s OPO was also calculated.
Time-dependent Cox regression models of access to transplantation and
waiting list mortality accounted for individual candidates changing between
periods of single-listing and periods of multiple-listing over time while
awaiting a transplant. In these time-to-event models, predictors of time to
transplantation and time to waiting list mortality were investigated by seg-
regating observation time while single-listed from follow-up time while
multiple-listed. In this way, each patient’s access to transplantation and
waiting list mortality was assessed over their entire tenure on the waiting
list, with appropriate attribution of single-listing or multiple-listing state to
both follow-up time and outcomes of interest. Patient waiting times were
calculated from waiting list registration date until transplantation, censored
at the earliest of the following: living related transplant/recovery, removal
from the waiting list (for any reason including death), or June 30, 2001. Pa-
tient waiting list survival times were calculated from waiting list registration
date until death, censored at the earliest of transplant, removal from the
waiting list (for reasons other than death), or June 30, 2001. The following
candidate covariates were included in the models of access to transplanta-
tion and waiting list mortality: age, gender, race, ethnicity, body mass index
(BMI), year of placement on the waiting list, ABO blood type, previous
transplants, diagnosis group, primary source of payment, and education.
For kidney analyses, the following covariates were also included: panel re-
active antibody (PRA) closest to day of wait-listing, relative transplantation
rate by human leukocyte antigen (HLA) marker index, dialysis modality, and
previous transfusions. For liver analyses, medical urgency status at day of
first placement on the waiting list was included.
Predictors of time to graft loss for kidney recipients and time to patient
death for liver recipients were investigated using Cox regression models to
determine the impact of multiple-listing at the time of transplant on these
outcomes. Post-transplant kidney graft survival times were calculated from
transplantation until death or graft failure, censored at the earlier of last
known follow-up date or June 30, 2001. Post-transplant liver patient sur-
vival times were calculated from transplant until death, censored at June
30, 2001. The following recipient, donor, and transplant covariates were
included in the models of post-transplant kidney graft and liver patient sur-
vival: recipient age, recipient gender, recipient race, recipient ethnicity, re-
cipient BMI, year transplanted, recipient ABO blood type, primary source of
payment, education, medical urgency status at transplant, previous trans-
plants, diagnosis group, donor age, donor gender, donor race, donor eth-
nicity, donor cause of death, cold ischemic time, and medical condition at
time of transplant (not hospitalized, hospitalized not in intensive care unit
[ICU], hospitalized in ICU). Additional covariates for liver recipients included
life support, reduced liver transplant, and creatinine greater than 2.0 mg/dL.
Additional covariates for kidney recipients included PRA closest to day of
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transplant, pretransplant transfusions, number of HLA mismatches, dual
kidney transplant, donor history of diabetes or hypertension, impaired renal
function (donor terminal serum creatinine greater than 1.5 mg/dL), and time
on dialysis.
Results
Prevalence and odds of multiple-listing among
patients on the waiting list
The prevalence and odds of multiple-listing for kidney wait-
ing list candidates are provided in Table 1. Overall, 5.8%
of kidney candidates were multiple-listed during the study
period. A range of demographic, biological, and socioeco-
nomic attributes was associated with multiple-listing. Kid-
ney transplant candidates who were age 0–17 (vs. age
34–49), female, African-American (vs. white), blood type
Table 1: Prevalence (%) and adjusted odds (AOR) of multiple-
listing among patients newly wait-listed for kidney transplant from
7/1/95 to 6/30/00
Measure n % AOR
All patients: 4743 5.8 –
Age at first listing:
0–9 16 2.1 0.39∗∗
10–17 66 3.6 0.72∗
18–34 974 6.7 1.13∗
35–49 1686 6.0 1.00 (ref)
50–65 1616 5.6 0.98
65 + 385 5.6 0.95
Gender:
Male 2895 6.0 1.00 (ref)
Female 1848 5.6 0.91∗
Race:
White 3323 6.4 1.00 (ref)
Black 1050 4.4 0.59∗∗
Other 370 6.4 0.90
ABO blood type:
A 1404 5.1 0.74∗∗
B 734 6.3 1.02
AB 147 4.6 0.66∗∗
O 2458 6.3 1.00 (ref)
PRA at first listing:
0–9 3352 5.6 1.00 (ref)
10–79 778 7.0 1.31∗∗
80 + 180 7.0 1.35∗∗
Payment:
Medicare 1899 5.1 1.00 (ref)
Medicaid 190 3.0 0.61∗∗
Private 2187 7.2 1.23∗∗
HMO 114 3.5 0.69∗∗
Education:
None, 0–12 years 1525 4.2 1.00 (ref)
College, Graduate 2027 7.9 1.67∗∗
Adjusted for registrant variables including age, gender, race,
ethnicity, BMI, year wait-listed, PRA closest to day of wait-listing,
relative transplantation rate by HLA marker index, ABO blood
type, primary source of payment, education, previous transplants,
diagnosis group, dialysis modality, previous transfusions, ratio of
OPO waiting list size to number of cadaveric kidneys recovered.
∗p < 0.05; ∗∗p < 0.0005.
A or AB (vs. blood type O), and who had Medicaid or a
health maintenance organization (HMO) as their primary
source of payment (vs. Medicare) were each significantly
less likely to multiple-list than patients in the indicated ref-
erence group. In contrast, patients with PRA 10 or greater
at first listing, who were age 18–34, college or graduate
school educated (vs. high school or less), and had private
insurance as their primary source of payment were each
significantly more likely to multiple-list. The probability of
multiple-listing increased by 9% with each unit increase in
the ratio of OPO waiting list size to cadaveric kidneys re-
covered annually in that OPO (mean ratio 3.35 ± 2.21; RR =
1.09; p = 0.0001).
The prevalence and odds of multiple-listing for liver wait-
ing list candidates are shown in Table 2. Overall, 3.3% of
liver candidates were multiple-listed during the study pe-
riod. A number of differences in the odds of multiple-listing
were noted between kidney and liver candidates. Unlike
kidney transplant candidates, multiple-listing rates for liver
did not differ by age. African-Americans and candidates of
Table 2: Prevalence (%) and adjusted odds (AOR) of multiple-
listing among patients newly wait-listed for liver transplant from
7/1/97 to 6/30/00
Measure n % AOR
All patients: 859 3.3 –
Age at first listing:
0–9 51 2.9 1.11
10–17 21 3.3 1.24
18–34 56 3.5 1.23
35–49 330 3.4 1.00 (ref)
50–65 345 3.2 0.92
65 + 56 3.2 0.96
Gender:
Male 561 3.6 1.00 (ref)
Female 298 2.8 0.79∗
Race:
White 780 3.5 1.00 (ref)
Black 49 2.1 0.68∗
Other 30 1.9 0.51∗
ABO blood type:
A 278 2.9 0.70∗∗
B 86 2.7 0.68∗
AB 25 2.5 0.62∗
O 470 3.8 1.00 (ref)
Payment:
Medicare 83 2.8 1.00 (ref)
Medicaid 48 1.2 0.45∗∗
Private 593 4.2 1.38∗
HMO 54 2.5 0.90
Education:
None, 0–12 years 243 2.7 1.00 (ref)
College, Graduate 334 4.7 1.55∗∗
Adjusted for registrant variables including age, gender, race,
ethnicity, BMI, year wait-listed, ABO blood type, primary source
of payment, education, medical urgency status at day of first
wait-listing, previous transplants, diagnosis group, ratio of OPO
waiting list size to number of cadaveric livers recovered.
∗p < 0.05; ∗∗p < 0.0005.
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other races had significantly lower odds than white candi-
dates of being multiple-listed. Liver candidates with A, B,
or AB blood types were significantly less likely to multiple-
list than patients with O blood type. Like kidney candidates,
males and those with college or graduate school education
were significantly more likely to multiple-list than females
and persons with less education, respectively. Multiple-
listing was significantly more likely among patients whose
primary source of payment was private insurance when
compared to patients whose primary source of payment
was Medicare, whereas Medicaid patients were signifi-
cantly less likely to multiple-list. The probability of multiple-
listing increased by 10% with each unit increase in the ratio
of OPO waiting list size to cadaveric livers recovered in the
OPO (mean ratio 1.99 ± 1.97; RR = 1.10; p = 0.0001).
Effect of distance and OPO waiting time on the choice
of second listing center
The distribution of distance from first listing center to sec-
ond listing center for multiple-listed transplant candidates
is shown in Figure 1. The majority of kidney patients who
were multiple-listed chose a second listing center within
one day’s drive of the original listing center (Figure 1a; me-
dian distance 135 miles). Figure 1b shows that multiple-
listed liver patients frequently chose a second listing center
that was much farther from the first listing center (median
distance 342 miles). These disparate data contrast with
the similar median distance between all possible combina-






































































































































Figure 1: Frequency distribution and cumulative proportion
of multiple-listed transplant candidates by distance between
first and subsequent transplant program listings, for (a) kid-
ney transplant candidates (median distance 135 miles) and
(b) liver transplant candidates (median distance 342 miles).
Across all multiple-listed kidney and liver patients, the av-
erage time until 25% of candidates received a transplant
(time to transplant) for the OPO of first listing was sig-
nificantly longer than that for the OPO of second listing
(kidney: 388 vs. 334 days; signed rank test; p < 0.0001;
liver: 297 vs. 188 days; signed rank test; p < 0.001).
Multiple-listing among transplant recipients
Overall, 7.3% (2792/38 505) of kidney transplant recipients
and 3.0% (370/12 396) of liver transplant recipients were
listed at centers in more than one OPO at the time of their
transplant. Nearly half (48.7%) of these kidney transplants
occurred at the original listing center. Of the 413 (14.8%)
multiple-listed kidney recipients who transferred accumu-
lated waiting time to the second center, 78.7% received a
transplant at the second center. Among multiple-listed liver
recipients, only 23.2% received a transplant at the original
listing center. Transfer of accumulated waiting time to the
second liver transplant center was requested by 26.5%,
and 91 of these 98 received a transplant at the second
center.
Kidney transplantation rates, waiting list mortality,
and graft outcome
The crude kidney transplant rate was 22.1 transplants per
100 patient years for single-listed patients and 41.3 per
100 patient years for multiple-listed candidates. Table 3
shows adjusted relative rates of kidney transplantation dur-
ing periods of multiple-listing. Transplantation rates were
88% higher overall (p < 0.0001) and 35% to 129% higher
by subgroup during periods of multiple-listing when com-
pared to periods on a single waiting list. These rates were
significantly higher for all patient subgroups examined ex-
cept those with HMO medical coverage, although the small
number of multiple-listed HMO candidates may have re-
sulted in limited statistical power for this subgroup. The
rate of transplantation for African-American patients dur-
ing periods of multiple-listing was twice that of African-
American patients during periods of single-listing (RR =
2.02; p < 0.0001). Candidates in 22 of 23 subgroups of
age, gender, race, ABO blood type, PRA level, medical in-
surance, and education level had kidney transplant rates
that were significantly higher than those for candidates
from the identical subgroups during periods of single listing
(RR = 1.42–2.29; all comparisons p < 0.0005 except age
10–17 [p < 0.05]).
The overall crude kidney waiting list mortality rate was
6.5% per year for single-listed candidates and 5.4% per
year for multiple-listed candidates. Adjusted kidney wait-
ing list mortality rates were lower during periods of
multiple-listing than during periods of single listing over-
all (RR = 0.72; p < 0.0925) and in every subgroup
(Table 3). Significantly lower waiting list mortality rates
were observed in 12 of 22 subgroups analyzed, including
adult candidates below age 65 (RR = 0.58–0.71), males
(RR = 0.66), non-African-Americans (RR = 0.44–0.65),
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Table 3: Kidney transplantation rates and wait-list mortality rates
during periods of multiple-listing compared to periods of single
listing. All analyses are adjusted for candidate variables
RR of transplant RR of wait-list morta-
during periods of lity during periods of
Subgroup multiple-listing multiple-listing
Overall: 1.88∗∗ 0.72



















PRA at first listing:
0–9 1.66∗∗ 0.65
10–79 2.13∗∗ 0.81







None, 0–12 years 1.89∗∗ 0.89
College, Graduate 1.93∗∗ 0.68∗∗
∗p < 0.05; ∗∗p < 0.0005; – insufficient data.
those with A, B, or O blood types (RR = 0.58–0.72), col-
lege or graduate school education level (RR = 0.68), and
Medicare (RR = 0.69) or Medicaid (RR = 0.22) as primary
insurance coverage.
The risk of kidney graft failure was significantly lower for
kidney transplant recipients who were multiple-listed at the
time they received their allograft when compared to those
resident on a single list at the time of transplant (RR = 0.90;
p = 0.03).
Liver transplantation rates, waiting list mortality,
and post-transplant mortality
The crude liver transplant rate was 39.3 per 100 patient
years for single-listed patients and 83.4 per 100 patient
years for multiple-listed candidates. Table 4 shows ad-
justed relative rates of liver transplantation and waiting
list mortality during periods of multiple-listing. Overall,
the transplantation rate was 195% higher while multiple-
Table 4: Liver transplantation rates and wait-list mortality rates
during periods of multiple-listing compared to periods of single
listing. All analyses are adjusted for candidate variables
RR of transplant RR of wait-list morta-
during periods of lity during periods of
Subgroup multiple-listing multiple-listing
Overall: 2.95∗∗ 1.40∗

























None, 0–12 years 3.16∗∗ 1.70∗
College, Graduate 2.43∗∗ 1.32
∗p < 0.05; ∗∗p < 0.0005; – insufficient data.
listed (p < 0.0001). Depending on the patient subgroup
examined, the rates of transplantation during periods of
multiple-listing were 82% to 641% higher than the rates of
transplantation during periods of single-listing, and were
significantly higher for all of the 19 patient subgroups with
sufficient data for analysis (all p < 0.0005). The highest rel-
ative rates of transplant during periods of multiple-listing
were seen for candidates with HMO medical coverage
(RR = 7.41), children less than 9 years old (RR = 4.80),
and African-Americans (RR = 4.64).
The overall crude liver waiting list mortality rate was 15.6%
per year for single-listed candidates and 14.2% per year
for multiple-listed candidates. However, in contrast to kid-
ney transplant candidates, who were found to have lower
crude and adjusted waiting list mortality while multiple-
listed, adjusted liver waiting list mortality rates during peri-
ods of multiple-listing were significantly higher than while
single-listed (RR = 1.40; p < 0.015); this was also true for
7 of 19 patient subgroups. Included in these subgroups
were candidates less than 9 years old, 18–49 years old,
of blood type B, with private medical insurance, with less
than college education, and African-American.
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The post-transplant mortality rate after liver transplanta-
tion among recipients who were multiple-listed at time of
transplant was not significantly different from the rate for
patients with a single listing at transplant (RR = 0.94; p =
0.6).
Discussion
In the current study, we provide analyses of national data
to inform the multiple-listing debate by examining the rela-
tive rate of transplantation during periods when candidates
were multiple-listed compared to periods of single listing.
The rate of access to kidney transplantation was signifi-
cantly higher while multiple-listed. The average multiple-
listed patient had 88% higher access to kidney transplant.
Every demographic, biological, and socioeconomic sub-
group benefited from multiple-listing, and the effect was
significant for all kidney subgroups except patients who
had HMO coverage for their transplant. Importantly, groups
known to have significantly diminished access to kidney
transplantation, including African-Americans, females, and
patients with blood types O and B (12), were all found to
have significantly higher transplant rates while multiple-
listed. In addition, candidates of lower educational attain-
ment and those with Medicaid insurance had significantly
higher transplant rates while multiple-listed. These socio-
economic factors have not been directly analyzed before,
though they have been addressed indirectly through anal-
ysis of ZIP code data (4,13).
A threefold transplant access advantage was identified for
liver transplant candidates. Every subgroup we studied had
a significantly higher transplant rate while multiple-listed.
The magnitude of the effect was even greater than for
kidney patients, with some patients experiencing as much
as a sixfold increase in transplant rate compared to single-
listing.
Only a small proportion of all candidates register on
multiple-lists. Sanfilippo et al. noted that 6.8% of candi-
dates placed on the kidney waiting list between 1987 and
1990 were multiple-listed (14), which is slightly higher than
the 5.8% reported here for a cohort of patients listed be-
tween 1995 and 2000. Ozminkowski et al. found that 4.5%
of kidney transplant candidates between 1987 and 1994
were multiple-listed, which may be an underestimate, be-
cause that study only included candidates multiple-listed
for at least 60 days within 30 months of initial listing (4). It
thus appears that multiple-listing by patients awaiting kid-
ney transplantation has not been increasing. To our knowl-
edge, there are no published studies specifically address-
ing multiple-listing for liver transplantation. In the current
study, 3.3% of liver candidates were multiple-listed.
We estimated the effect of multiple-listing on the wait-
ing time of single-listed candidates as a way to gauge the
harm imparted by this practice. With a relative rate of kid-
ney transplant that is 1.88 times that for single-listed candi-
dates, waiting time for multiple-listed candidates is almost
50% less. Applying the published overall median waiting
time to kidney transplant of 152 weeks for the study pe-
riod (1), waiting time for multiple-listed candidates is ap-
proximately 83 weeks. The waiting time for single-listed
patients is calculated to be 156 weeks, about 4 weeks
longer than the overall median. Calculations for liver trans-
plant patients indicate that multiple-listing results in a wait-
ing time that is also about 4 weeks longer than the overall
median for single-listed liver candidates.
Since OPOs of secondary listing have shorter waiting
times, on average, than primary listing OPOs, the prac-
tice of multiple-listing should tend to reduce waiting time
disparities among OPOs. When a multiple-listed candidate
receives a transplant in an OPO with a shorter waiting time,
their consequent removal from the waiting list of the origi-
nal OPO reduces the waiting time there. Conversely, wait-
ing time is slightly increased for the remaining single-listed
candidates in the secondary OPO where the transplant
occurred.
In order to put these findings into context with other dis-
crepancies in access to transplantation, one might consider
how the effects of multiple-listing compare to existing re-
gional discrepancies in waiting time in the United States.
Under current allocation policy for kidneys and livers (15),
most donated organs are distributed first to local patients
awaiting transplant at a center served by the OPO servic-
ing the donor hospital, then to a larger region, and then to
the nation as a whole. Median waiting times for kidneys
and livers at OPOs with the lowest and highest median
waiting times demonstrate more than 10-fold and 22-fold
differences, respectively (Figure 2). The effects of multiple-
listing, as currently practiced, appear quite modest in com-
parison. In fact, regional disparities in waiting time would
still dwarf the impact of multiple-listing even if its use were,
for example, to double. Given the large differences in wait-
ing time by OPO, the multiple-listed patients help to reduce
these regional discrepancies, albeit to a small extent.
We found an association between multiple-listing and
decreased kidney waiting list mortality rate. Although
these results were significant only for patients with se-
lected characteristics (adults 65 and younger; males; non-
African-Americans; A, B, and O blood types; Medicare and
Medicaid insurance, at least a college education), the anal-
yses suggest that multiple-listed kidney patients may have
lower acuity of disease. Transplantation while multiple-
listed was associated with significantly better renal graft
outcome. Conversely, liver candidates had significantly
higher waiting list mortality while multiple-listed. Since
liver transplant candidates tend to be sicker than patients
awaiting kidney transplant and have no fallback therapy
like dialysis, disease acuity may be a driver of multiple-
listing for these individuals. Liver recipients who were
multiple-listed at the time of transplantation showed no




















































































Figure 2: Ranked median time to transplant by OPO for kid-
ney (a) and liver (b) candidates. Values for lowest and highest
OPOs are shown, as well as the US median. OPOs that have not
yet reached the median are grouped. Also shown are median es-
timated waiting times for multiple-listed and single-listed kidney
and liver candidates.
difference in post-transplant survival compared to single
listed recipients.
Analyses of the choice of second center by patients who
elect to multiple-list indicate that kidney candidates were
willing to travel modest distances, the equivalent of a 2–3-h
highway trip. There was a 14% lower 25th percentile wait-
ing time in the OPO serving the second center. For liver
patients, average distance traveled to the second center
was farther (median 342 miles), and the OPO serving the
second center had, on average, a much shorter (37%) wait-
ing time than that serving the original center. The difference
in behavior of candidates for these two organs may reflect
the higher acuity of illness and the lack of an alternative
life-sustaining therapy for liver candidates.
In contrast to the consistent transplant access benefit re-
sulting from multiple-listing of kidney and liver patients,
only a small fraction of candidates utilize this option, and
striking demographic and socioeconomic differences were
seen for this group. Although it is beyond the scope of this
investigation to discern the specific reasons why some pa-
tients multiple-list and some do not, there is clearly a need
for better education, as it is likely that many patients are
unaware that this option is available to them. Candidates in
OPOs with long waiting times would especially benefit by
multiple-listing in OPOs with shorter waiting times. Finally,
it appears that enlargement of the first unit of geographic
distribution of organs beyond the current OPO boundaries
would tend to reduce geographic waiting time disparities
for all patient subgroups and benefit patients whose bio-
logical attributes require larger donor pools, rather than the
select few who multiple-list.
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